Table 4.
Clinical trials of anti-cancer therapies targeting Axl
| Methods of drug application | Disease type | Phase | Current status | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Bemcentinib (before surgery); Bemcentinib (after surgery) | Brain and central nervous system tumors | 1 | Active | NCT03965494 |
| Bemcentinib; docetaxel | Non-small cell lung cancer | 1 | Active | NCT02922777 |
| Bemcentinib; pembrolizumab | Triple-negative breast cancer; inflammatory breast cancer stage IV | 2 | Terminated | NCT03184558 |
| Bemcentinib; cytarabine; decitabine | Acute myeloid leukemia; myelodysplastic syndromes | 1/2 | Active | NCT02488408 |
| Bemcentinib; pembrolizumab | Lung cancer metastatic; NSCLC stage IV; adenocarcinoma of lung | 2 | Completed | NCT03184571 |
| Bemcentinib+pembrolizumab; Bemcentinib+dabrafenib and trametinib; pembrolizumab; dabrafenib and trametinib | Melanoma | 1/2 | Active | NCT02872259 |
| Erlotinib; bemcentinib | Non-small cell lung cancer | 1/2 | Completed | NCT02424617 |
| Bemcentinib | Acute myeloid leukemia; high-risk myelodysplastic syndrome; low-risk myelodysplastic syndrome | 2 | Completed | NCT03824080 |
| Rucaparib; abemaciclib; pembrolizumab and bemcentinib | Mesothelioma, malignant | 2 | Active | NCT03654833 |
Bemcentinib (BGB324) a highly selective inhibitor of Axl